,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['paradigm']
breathtaking results from db04 presented by shaun modi. benefit for t-dxd irrespective of subtype &amp; 1+/2+ ihc results a paradigm shift that breaks through traditional subgroup classification deserving of the standing ovation!!! #asco22 
Chief, Division of Breast Oncology @DanaFarber
Tennis fan
Mother of two teenage girls